PDF(Pubmed)
Abstract：
Multidrug resistance is a serious problem in modern medicine and the reason for the failure of various therapies. A particularly important problem is the occurrence of multidrug resistance in cancer therapies which affects many cancer patients. Observations on the effect of metformin-a well-known hypoglycemic drug used in the treatment of type 2 diabetes-on cancer cells indicate the possibility of an interaction of this substance with drugs already used and, as a result, an increase in the sensitivity of cancer cells to cytostatics. The aim of this study was to evaluate the effect of metformin on the occurrence of multidrug resistance of breast cancer cells. The MCF-7-sensitive cell line and the MCF-7/DX cytostatic-resistant cell line were used for this study. WST-1 and LDH assays were used to evaluate the effects of metformin and doxorubicin on cell proliferation and viability. The effect of metformin on increasing the sensitivity of MCF-7 and MCF-7/DX cells to doxorubicin was evaluated in an MDR test. The participation of metformin in increasing the sensitivity of resistant cells to the effect of the cytostatic (doxorubicin) has been demonstrated.
摘要：
多药耐药是现代医学中的一个严重问题，也是各种疗法失败的原因。一个特别重要的问题是癌症治疗中多药耐药性的发生，这影响了许多癌症患者。对二甲双胍（一种用于治疗2型糖尿病的众所周知的降血糖药物）对癌细胞的影响的观察表明，该物质与已经使用的药物相互作用的可能性，因此,癌细胞对细胞抑制剂的敏感性增加。本研究旨在评价二甲双胍对乳腺癌细胞多药耐药发生的影响。MCF-7敏感细胞系和MCF-7/DX细胞抑制抗性细胞系用于本研究。使用WST-1和LDH测定来评估二甲双胍和多柔比星对细胞增殖和活力的影响。在MDR试验中评价二甲双胍对增加MCF-7和MCF-7/DX细胞对多柔比星的敏感性的作用。已证明二甲双胍参与增加抗性细胞对细胞抑制剂（多柔比星）作用的敏感性。
